echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Express Roche's PD-1/LAG-3 bispecific antibody applied for clinical application in China

    Express Roche's PD-1/LAG-3 bispecific antibody applied for clinical application in China

    • Last Update: 2021-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    The Center for Drug Evaluation (CDE) of the China National Medical Products Administration showed that the RO7247669 injection being developed by Roche has been declared for clinical use in China and was accepted on July 2


    Screenshot source: CDE official website

    Bispecific antibody is an antibody that can specifically bind to two different antigens


    RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 developed by Roche


    LAG-3 is called lymphocyte activation gene-3.


    Information published on the Clinicaltrials.


    Reference materials:

    [1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.